Gynomax® XL Vaginal Ovule and Treatment of Common Vaginal Infections

Rujittika MUNGMUNPUNTIPANTIPA, Viroj WIWANITKITB

A Private Academic Consultant, Bangkok, Thailand
B Dr DY Patil University, Pune, India

We would like to discuss on the publication “The Efficacy and Safety of Gynomax® XL Vaginal Ovule in the Treatment of Common Vaginal Infections: A Single-arm Clinical Trial.”1 Tavmergen et al. mentioned that “Gynomax® XL vaginal ovules administered once daily for three consecutive days provide effective and safe treatment in patients with bacterial vaginosis (BV), candidal vulvovaginitis (CVV), and MVIs.”1 We agree that the score might be useful for management of vaginal infections. However, as a single arm trial, it cannot conclude whether it is effective than no therapy or not. Finally, the background degree of infection should be discussed. Success in management of vaginal infection is also associated with background severity, which can be access by vaginosis scoring.2 A correlation to vaginosis score might give useful information on the efficacy of the drug.

Source of Finance
During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

Conflict of Interest
No conflicts of interest between the authors and/or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

Authorship Contributions
All authors contributed equally while this study preparing.

REFERENCES

Correspondence: Rujittika MUNGMUNPUNTIPANTIP
Private Academic Consultant, Bangkok, Thailand
E-mail: rujittika@gmail.com
We strongly agree and respect to the forementioned scoring system’s usefulness. There is no must to run such prospective single arm study depending on vaginal infection score. At the background of our study, universally accepted laboratory and clinical criteria are used on a well accepted scientific basis. The aim of the study is to evaluate the effect Gynomax (Exeltis İlaç San. ve Tic. A.Ş., Türkiye) ovule in the treatment of laboratory and clinically confirmed vaginal infections. This study was done on the basis of detection of pathological microorganisms which should not exist in normal vaginal flora. So the correlation of the drug’s efficacy on elimination of the pathological organisms is a well accepted method for this kind of single arm studies. Thank you very much for your contribution.

Gynomax® XL Vaginal Ovule and Treatment of Common Vaginal Infections

Erol TAVMERGEN

Department of Obstetrics and Gynecology, Ege University Faculty of Medicine, İzmir, Türkiye

Correspondence: Rujittika MUNGMUNPUNTIPANTIP
Private Academic Consultant, Bangkok, Thailand
E-mail: rujittika@gmail.com

Peer review under responsibility of Journal of Clinical Obstetrics & Gynecology.

Received: 31 Jan 2022   Accepted: 08 Feb 2022   Available online: 10 Mar 2022

2619-9467 / Copyright © 2022 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).